Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho family GTPase 1 (RND1) is a small (~21 kDa) signaling GTPase protein, encoded by the RND1 gene and belonging to the Rho family subgroup known as Rnd[1][3]. Unlike most GTPases, RND1 lacks intrinsic GTPase activity, constitutively binds GTP, and does not cycle between active/inactive forms in the standard manner[3][4]. RND1 is chiefly involved in regulating actin cytoskeleton organization and cell structure in response to extracellular signals[1][3][4]. In neurons, it participates in extending neurites and affects microtubule dynamics[2][3]. The protein interacts with several signaling effectors, including stathmin2 (neuronal growth), GRB7, PLXNB1, PDE6D, ARHGAP5, and UBXD5[1]. Disruption of its function or aberrant signaling via RND1 and related Rho GTPases has been implicated in cancer progression and developmental disorders[2][3]. The lack of intrinsic GTPase activity distinguishes RND1 from many classical Rho proteins[4].
For theoretical drugs or tool compounds: Inhibition or modulation of GTPase activity; Disruption or enhancement of actin cytoskeleton organization; Affecting downstream effectors (e.g., stathmin2, microtubule-regulating proteins).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho family GTPase 1 (RND1).